Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate CG Oncology Inc before investing.

In this article, we go over a few key elements for understanding CG Oncology Inc’s stock price such as:

• CG Oncology Inc’s current stock price and volume
• Why CG Oncology Inc’s stock price changed recently
• Upgrades and downgrades for CGON from analysts
• CGON’s stock price momentum as measured by its relative strength

About CG Oncology Inc (CGON)

Before we jump into CG Oncology Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Want to learn more about CG Oncology Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about CG Oncology Inc.

CG Oncology Inc’s Stock Price as of Market Close

As of July 19, 2024, 4:00 PM, CST, CG Oncology Inc’s stock price was $35.22.

CG Oncology Inc is down 4.08% from its previous closing price of $36.72.

During the last market session, CG Oncology Inc’s stock traded between $36.42 and $38.69. Currently, there are 66.64 million shares of CG Oncology Inc stock available for purchase.

Unfortunately, CG Oncology Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

CG Oncology Inc Stock Price History

CG Oncology Inc’s (CGON) price is currently up 11.56% so far this month.

During the month of July, CG Oncology Inc’s stock price has reached a high of $38.97 and a low of $30.20.

Over the last year, CG Oncology Inc has hit prices as high as $50.23 and as low as $25.77.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused CG Oncology Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 18, 2024, there were 3 analysts who downgraded CG Oncology Inc’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate CG Oncology Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on CG Oncology Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about CG Oncology Inc (CGON) by visiting AAII Stock Evaluator.

Relative Price Strength of CG Oncology Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 18, 2024, CG Oncology Inc has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how CG Oncology Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

CG Oncology Inc Stock Price: Bottom Line

As of July 19, 2024, CG Oncology Inc’s stock price is $35.22, which is down 4.08% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like CG Oncology Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.